Literature DB >> 29556000

Environmental allergens induce allergic inflammation through proteolytic maturation of IL-33.

Corinne Cayrol1, Anais Duval2, Pauline Schmitt2, Stephane Roga2, Mylène Camus2, Alexandre Stella2, Odile Burlet-Schiltz2, Anne Gonzalez-de-Peredo2, Jean-Philippe Girard3.   

Abstract

Allergic inflammation has crucial roles in allergic diseases such as asthma. It is therefore important to understand why and how the immune system responds to allergens. Here we found that full-length interleukin 33 (IL-33FL), an alarmin cytokine with critical roles in type 2 immunity and asthma, functioned as a protease sensor that detected proteolytic activities associated with various environmental allergens across four kingdoms, including fungi, house dust mites, bacteria and pollens. When exposed to allergen proteases, IL-33FL was rapidly cleaved in its central 'sensor' domain, which led to activation of the production of type 2 cytokines in group 2 innate lymphoid cells. Preventing cleavage of IL-33FL reduced allergic airway inflammation. Our findings reveal a molecular mechanism for the rapid induction of allergic type 2 inflammation following allergen exposure, with important implications for allergic diseases.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29556000     DOI: 10.1038/s41590-018-0067-5

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  83 in total

Review 1.  Environmental exposures and mechanisms in allergy and asthma development.

Authors:  Liza Bronner Murrison; Eric B Brandt; Jocelyn Biagini Myers; Gurjit K Khurana Hershey
Journal:  J Clin Invest       Date:  2019-02-11       Impact factor: 14.808

2.  Interleukin-33 contributes to disease severity in Dengue virus infection in mice.

Authors:  Rafael E Marques; Anne-Gaëlle Besnard; Isabelle Maillet; Caio T Fagundes; Danielle G Souza; Bernhard Ryffel; Mauro M Teixeira; Foo Y Liew; Rodrigo Guabiraba
Journal:  Immunology       Date:  2018-09-10       Impact factor: 7.397

3.  Substance P Release by Sensory Neurons Triggers Dendritic Cell Migration and Initiates the Type-2 Immune Response to Allergens.

Authors:  Caroline Perner; Cameron H Flayer; Xueping Zhu; Pamela A Aderhold; Zaynah N A Dewan; Tiphaine Voisin; Ryan B Camire; Ohn A Chow; Isaac M Chiu; Caroline L Sokol
Journal:  Immunity       Date:  2020-10-23       Impact factor: 31.745

4.  Allergy: An alarmin cut.

Authors:  Lucy Bird
Journal:  Nat Rev Immunol       Date:  2018-04-04       Impact factor: 53.106

5.  Identification of the IL-33 protein segment that controls subcellular localization, extracellular secretion, and functional maturation.

Authors:  Irina G Luzina; Andrew Clerman; Rita Fishelevich; Nevins W Todd; Virginia Lockatell; Sergei P Atamas
Journal:  Cytokine       Date:  2019-03-08       Impact factor: 3.861

Review 6.  Are We Meeting the Promise of Endotypes and Precision Medicine in Asthma?

Authors:  Anuradha Ray; Matthew Camiolo; Anne Fitzpatrick; Marc Gauthier; Sally E Wenzel
Journal:  Physiol Rev       Date:  2020-01-09       Impact factor: 37.312

7.  Selective cleavage of fibrinogen by diverse proteinases initiates innate allergic and antifungal immunity through CD11b.

Authors:  Cameron T Landers; Hui-Ying Tung; J Morgan Knight; Matthew C Madison; Yifan Wu; Zhimin Zeng; Paul C Porter; Antony Rodriguez; Matthew J Flick; Farrah Kheradmand; David B Corry
Journal:  J Biol Chem       Date:  2019-04-16       Impact factor: 5.157

8.  MicroRNA-30a Targets ATG5 and Attenuates Airway Fibrosis in Asthma by Suppressing Autophagy.

Authors:  Bin Bin Li; Yun Long Chen; Fuzhen Pang
Journal:  Inflammation       Date:  2020-02       Impact factor: 4.092

Review 9.  All along the watchtower: group 2 innate lymphoid cells in allergic responses.

Authors:  Madelene W Dahlgren; Ari B Molofsky
Journal:  Curr Opin Immunol       Date:  2018-06-01       Impact factor: 7.486

Review 10.  Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis.

Authors:  Nan Yang; Zeyu Chen; Xilin Zhang; Yuling Shi
Journal:  BioDrugs       Date:  2021-07-02       Impact factor: 5.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.